Truist Securities Raises Merck Price Target to $142 From $139, Maintains Buy Rating
Merck & Co Analyst Ratings
Maintaining Hold on Merck & Co. Amidst Sotatercept's Promising Developments and Revised Sales Projections
Merck & Company (MRK) Gets a Buy From Cantor Fitzgerald
Societe Generale Downgrades Merck to Sell From Hold, Raises Price Target to $104 From $103
Societe General Cuts Merck to Sell, Cites Keytruda Patent Expiry
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $135 Price Target
Merck & Co Analyst Ratings
Critical Insights From Merck & Co Analyst Ratings: What You Need To Know
Merck & Co Analyst Ratings
Merck & Co Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $135 Price Target
Merck & Co Analyst Ratings
Merck & Co: Strong Buy Rating on Robust Q4 Earnings and Promising Pipeline Outlook
Major Bank Ratings | Goldman Sachs: Raising MSD's Target Price to $134 to Maintain a “Buy” Rating
Merck & Co Analyst Ratings
Merck & Co Analyst Ratings
Goldman Sachs Raises Merck's Price Target to $134 From $128, Maintains Buy Rating
Deutsche Bank Adjusts Merck & Company Price Target to $135 From $115, Maintains Buy Rating
BofA Securities Raises Merck Price Target to $135 From $130, Maintains Buy Rating
No Data